Despite the success of desensitization protocols, antibody-mediated rejection (AMR)
remains a significant contributor to renal allograft failure in patients with donor-specific …

Therapeutic apheresis is a cornerstone of therapy for several conditions in transplantation
medicine and is available in different technical variants. In the setting of kidney …

Objective To evaluate the diagnostic performance of donor-derived plasma cell-free DNA
(cfDNA) in discriminating antibody-mediated rejection (ABMR) or de novo donor-specific …

Mesenchymal stem cell (MSCs) therapy has already been studied in kidney transplant
recipients (KTRs), and the available data showed that it is safe and well tolerated. The aim of …

Successful transplantation outcome is the final goal in most end stage and nonfunctional
organs; however, despite using different therapeutic strategies, antibody-mediated rejection …

Proteasome inhibitor bortezomib has been used in the treatment of refractory cases of acute
and chronic antibody-mediated rejection (AMR) in kidney transplant recipients. However, its …

Objective The present study aimed to investigate the functional role of bortezomib in the
development of acute allograft rejection (AR) after renal transplant. Methods The mouse …

Background Treatment of antibody-mediated rejection (AMR) is one of the main problems
after kidney transplantation (KTx). The results of intensive AMR treatment with …

2• Abu-Dalle I, Reljic T, Nishihori T, et al. Extracorporeal photopheresis in steroid-refractory
acute or chronic graft-versus-host disease: results of a systematic review of prospective …

This article reviews the current treatment strategies of antibody-mediated rejection in kidney
transplantation, which is increasingly recognized as the leading immunological cause of …